{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T18:51:37Z","timestamp":1793386297568,"version":"4.5.0"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2023,10,16]],"date-time":"2023-10-16T00:00:00Z","timestamp":1697414400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2023,10,16]],"date-time":"2023-10-16T00:00:00Z","timestamp":1697414400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Pfizer Japan Inc."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2023,12]]},"DOI":"10.1007\/s12325-023-02692-x","type":"journal-article","created":{"date-parts":[[2023,10,16]],"date-time":"2023-10-16T05:01:41Z","timestamp":1697432501000},"page":"5519-5535","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Importance of Regular Examination and Follow-up in Pediatric Patients with Neurogenic Bladder: 24-Month Follow-up Study Using a Japanese Health Insurance Database"],"prefix":"10.1007","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5135-2987","authenticated-orcid":false,"given":"Naoko","family":"Izumi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeya","family":"Kitta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takahiko","family":"Mitsui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,10,16]]},"reference":[{"key":"2692_CR1","doi-asserted-by":"publisher","first-page":"16306","DOI":"10.1038\/s41598-022-20731-5","volume":"12","author":"S Shan","year":"2022","unstructured":"Shan S, Zhu W, Zhang G, et al. Video-urodynamics efficacy of sacral neuromodulation for neurogenic bladder guided by three-dimensional imaging CT and C-arm fluoroscopy: a single-center prospective study. Sci Rep. 2022;12:16306.","journal-title":"Sci Rep"},{"key":"2692_CR2","doi-asserted-by":"publisher","first-page":"1278","DOI":"10.1002\/nau.23981","volume":"38","author":"A Jaggi","year":"2019","unstructured":"Jaggi A, Nazir J, Fatoye F, et al. Drug utilization patterns and healthcare resource use and costs in patients with neurogenic bladder in the United Kingdom: a retrospective primary care database study. Neurourol Urodyn. 2019;38:1278\u201389.","journal-title":"Neurourol Urodyn"},{"key":"2692_CR3","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1002\/nau.21003","volume":"30","author":"A Manack","year":"2011","unstructured":"Manack A, Motsko SP, Haag-Molkenteller C, et al. Epidemiology and healthcare utilization of neurogenic bladder patients in a US claims database. Neurourol Urodyn. 2011;30:395\u2013401.","journal-title":"Neurourol Urodyn"},{"key":"2692_CR4","doi-asserted-by":"publisher","first-page":"479","DOI":"10.3233\/PRM-200712","volume":"13","author":"DB Joseph","year":"2020","unstructured":"Joseph DB, Baum MA, Tanaka ST, et al. Urologic guidelines for the care and management of people with spina bifida. J Pediatr Rehabil Med. 2020;13:479\u201389.","journal-title":"J Pediatr Rehabil Med"},{"key":"2692_CR5","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1007\/s40272-017-0249-x","volume":"19","author":"P Kroll","year":"2017","unstructured":"Kroll P. Pharmacotherapy for pediatric neurogenic bladder. Paediatr Drugs. 2017;19:463\u201378.","journal-title":"Paediatr Drugs"},{"key":"2692_CR6","doi-asserted-by":"publisher","first-page":"3191","DOI":"10.3390\/jcm12093191","volume":"12","author":"T Kitta","year":"2023","unstructured":"Kitta T, Mitsui T, Izumi N. Diagnosis and treatment of Japanese children with neurogenic bladder: analysis of data from a national health insurance database. J Clin Med. 2023;12:3191.","journal-title":"J Clin Med"},{"key":"2692_CR7","unstructured":"JMDC Claims Database. https:\/\/www.jmdc.co.jp\/en\/jmdc-claims-database\/. Accessed 3 Jan 2023."},{"key":"2692_CR8","unstructured":"Statistics Bureau of Japan. https:\/\/www.stat.go.jp\/english\/info\/news\/20220228.html. Accessed 3 Jan 2023."},{"key":"2692_CR9","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1002\/jgf2.422","volume":"22","author":"K Nagai","year":"2021","unstructured":"Nagai K, Tanaka T, Kodaira N, Kimura S, Takahashi Y, Nakayama T. Data resource profile: JMDC claims database sourced from health insurance societies. J Gen Fam Med. 2021;22:118\u201327.","journal-title":"J Gen Fam Med"},{"key":"2692_CR10","unstructured":"Ministry of Health, Labour and Welfare. Ethical guidelines for medical and health research involving human subjects (English translation, March 2015). https:\/\/www.mhlw.go.jp\/file\/06-Seisakujouhou-10600000-Daijinkanboukouseikagakuka\/0000080278.pdf. Accessed 3 Jan 2023."},{"key":"2692_CR11","unstructured":"The Japanese Continence Society. Clinical guidelines for lower urinary tract dysfunction in patients with spina bifida. https:\/\/www.urol.or.jp\/lib\/files\/other\/guideline\/31_lower-urinary_dysfunction_2017.pdf. Accessed 3 Jan 2023."},{"key":"2692_CR12","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1002\/nau.24810","volume":"41","author":"G Kane","year":"2022","unstructured":"Kane G, Doyle M, Kelly G, Subramaniam R, Cascio S. A multinational survey on the management of the urinary tract in newborns with spina bifida: are we following current EAU\/ESPU guidelines? Neurourol Urodyn. 2022;41:264\u201374.","journal-title":"Neurourol Urodyn"},{"key":"2692_CR13","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1002\/nau.24211","volume":"39","author":"R Stein","year":"2020","unstructured":"Stein R, Bogaert G, Dogan HS, et al. EAU\/ESPU guidelines on the management of neurogenic bladder in children and adolescent part I diagnostics and conservative treatment. Neurourol Urodyn. 2020;39:45\u201357.","journal-title":"Neurourol Urodyn"},{"key":"2692_CR14","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1002\/nau.24248","volume":"39","author":"R Stein","year":"2020","unstructured":"Stein R, Bogaert G, Dogan HS, et al. EAU\/ESPU guidelines on the management of neurogenic bladder in children and adolescent part II operative management. Neurourol Urodyn. 2020;39:498\u2013506.","journal-title":"Neurourol Urodyn"},{"key":"2692_CR15","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1016\/j.urology.2021.12.027","volume":"164","author":"M Jiang","year":"2022","unstructured":"Jiang M, Deng J, Zhou G, Li S, Liu G. Risk factors for recurrent urinary tract infection in children with neurogenic bladder following clean intermittent catheterization. Urology. 2022;164:224\u20139.","journal-title":"Urology"},{"key":"2692_CR16","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1016\/j.ucl.2015.05.006","volume":"42","author":"MJ McKibben","year":"2015","unstructured":"McKibben MJ, Seed P, Ross SS, Borawski KM. Urinary tract infection and neurogenic bladder. Urol Clin North Am. 2015;42:527\u201336.","journal-title":"Urol Clin North Am"},{"key":"2692_CR17","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2015-2982","volume":"137","author":"N Shaikh","year":"2016","unstructured":"Shaikh N, Hoberman A, Keren R, et al. Recurrent urinary tract infections in children with bladder and bowel dysfunction. Pediatrics. 2016;137:e20152982.","journal-title":"Pediatrics"},{"key":"2692_CR18","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1007\/s11884-016-0390-3","volume":"11","author":"L Martinez","year":"2016","unstructured":"Martinez L, Neshatian L, Khavari R. Neurogenic bowel dysfunction in patients with neurogenic bladder. Curr Bladder Dysfunct Rep. 2016;11:334\u201340.","journal-title":"Curr Bladder Dysfunct Rep"},{"key":"2692_CR19","doi-asserted-by":"publisher","first-page":"1669","DOI":"10.3390\/jcm10081669","volume":"10","author":"G Mosiello","year":"2021","unstructured":"Mosiello G, Safder S, Marshall D, Rolle U, Benninga MA. Neurogenic bowel dysfunction in children and adolescents. J Clin Med. 2021;10:1669.","journal-title":"J Clin Med"},{"key":"2692_CR20","doi-asserted-by":"publisher","first-page":"16","DOI":"10.21037\/amj.2019.02.02","volume":"4","author":"A Jaggi","year":"2019","unstructured":"Jaggi A, Fatoye F. Sub-optimal diagnosis of neurogenic bladder among general practitioners in the United Kingdom-evidence from the Clinical Practice Research Datalink. AME Med J. 2019;4:16.","journal-title":"AME Med J"},{"key":"2692_CR21","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1111\/j.1757-5672.2011.00090.x","volume":"3","author":"A Kanematsu","year":"2011","unstructured":"Kanematsu A, Johnin K, Yoshimura K, Imamura M, Ogawa O. Comparison of the effects by obybutynin and tolterodine on spina bifida patients: a pilot crossover study. Low Urin Tract Symptoms. 2011;3:99\u2013103.","journal-title":"Low Urin Tract Symptoms"},{"key":"2692_CR22","first-page":"182","volume":"10","author":"MJ Kennelly","year":"2008","unstructured":"Kennelly MJ, Devoe WB. Overactive bladder: pharmacologic treatments in the neurogenic population. Rev Urol. 2008;10:182\u201391.","journal-title":"Rev Urol"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-023-02692-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-023-02692-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-023-02692-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,27]],"date-time":"2023-10-27T11:11:25Z","timestamp":1698405085000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-023-02692-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,16]]},"references-count":22,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2023,12]]}},"alternative-id":["2692"],"URL":"https:\/\/doi.org\/10.1007\/s12325-023-02692-x","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10,16]]},"assertion":[{"value":"1 August 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 September 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 October 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Naoko Izumi was involved in research and preparation of the manuscript as an employee of Pfizer Japan Inc. Takeya Kitta and Takahiko Mitsui did not receive any compensation related to this study, from Pfizer. We thank the children who were included in the study anonymously.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This study did not require institutional review board or independent ethics committee approval because the guidelines do not require such approval for information that has already been anonymized. Patient consent was waived since the guidelines do not require consent for anonymized information.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}